Targeted Enzyme Therapy of Experimental Glomerulonephritis in Rats

Richard B. White,* Lia Lowrie,† John E. Stork,‡ Samy S. Iskandar,§ Michael E. Lamm,* and Steven N. Emancipator* 
Institute of Pathology* and Department of Pediatrics,† Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio 44106; and Department of Pathology,§ Bowman Gray School of Medicine, Winston-Salem, North Carolina 27103

Abstract

We sought to determine whether systemic administration of proteases ameliorates membranous nephritis induced in rats by immunization and challenge with cationic bovine gamma globulin, and whether targeting of protease to glomerular capillaries increases efficacy. Proteases substituted with biotin were targeted via the cationic protein avidin A, which by virtue of its charge has affinity for the glomerular basement membrane. Despite identical pretreatment proteinuria, rats given untargeted protease (biotin-conjugated without avidin, or unconjugated plus avidin) had significantly less proteinuria than saline-treated controls and nephrotic rats given avidin plus biotin-conjugated (targeted) protease had even less proteinuria and reduced glomerular rat IgG and C3. Among more severely nephrotic rats, targeted protease was again more effective than untargeted protease at reducing proteinuria, and also decreased the size of electron-dense glomerular deposits, hypercholerolemia, and creatinurina. Inactivated targeted proteases had no effect on proteinuria, hypercholerolemia, or azotemia. Finally, active targeted protease did not affect proteinuria in the nonimmune mediated nephrosis induced by puromycin aminonucleoside. We conclude that systemic protease can specifically diminish glomerular immune deposits, proteinuria, hyperlipidemia, and creatinurina associated with experimental immune complex glomerulonephritis but not toxic nephropsis, and that targeted protease is more effective than untargeted protease. (J. Clin. Invest. 1991. 87:1819–1827.) Key words: avidin • basement membrane • biotin • endopeptide • glomerulonephritis • hydrolases

Introduction

Immune complex glomerulonephritis is often a chronic progressive disease in which multiple, interrelated mechanisms appear to underlie altered glomerular function and glomerulosclerosis (1). To the extent that multiple inflammatory pathways lead to the same outcome, the most efficient pharmacologic intervention would be directed to mediators common to different pathways. On the other hand, attenuation of the glomerular immune deposits themselves would offer a therapeutic modality common to a variety of glomerulonephritides. Indeed, the most widely applied treatments operate by virtue of immunosuppressive effects (2–7) or removing immunoglobulin aggregates from the circulation (8, 9). In selected experimental systems where the antigen is known, the hazards of general immunosuppression and/or plasmapheresis have been avoided by dissolving immune deposits from glomeruli through systemic administration of large excesses of the very antigen which evoked formation of the immune complexes (10–12). A similar approach, assuming that rheumatoid factor is an important nephritogenic antibody in human lupus nephritis, has used high doses of human γ-globulin to ameliorate glomerular dysfunction in patients with this disease (13).

We (14, 15) and others (16) independently reasoned that dissolution of deposited immune complexes might be achieved without knowledge of the culprit antigen by enzymatic cleavage of the immune lattice. Proteases administered intraperitoneally, intravenously, and orally to mice, rats, and rabbits significantly reduced the glomerular immune deposits associated with passive serum sickness (14, 16) and the heterologous and autologous phases of passive Heymann nephritis (15) at doses devoid of overt toxicity. Proteases also decreased the proteinuria of passive Heymann nephritis (15).

In the present work, we sought to determine whether protease therapy is effective on the glomerular immune deposits of active serum sickness nephritis and whether such treatment would abate the elements of the attendant nephrotic syndrome. Active serum sickness was induced in rats with cationic bovine γ-globulin (cBGG)1 (17). In this model the cationic nature of the antigen promotes glomerular capillary wall deposition of antigen and antigen/antibody complexes by binding electrostatically to the polyanionic heparan sulfate indigenous to the capillary basement membrane (18). We also hypothesized that cationic avidin could target biotinylated proteolytic enzymes to localize in the same distribution as cationic immune complexes, thereby improving the efficacy of the enzymes in removing glomerular immune deposits. To test the hypothesis we exploited the high binding affinity of the naturally cationic protein avidin A for biotin to target biotinyl proteases to sites where cationic proteins lodge.

Methods

Pilot studies on feasibility of targeting. 18 male 200-g Sprague-Dawley rats (Zivic-Miller Farms, Austin Park, PA) received 1 mg of avidin A (Sigma Chemical Co., St. Louis, MO) in 0.5 ml of saline i.v., and another six rats were given saline alone. An additional six rats were un-

1. Abbreviations used in this paper: b, biotinylated; cBGG, cationic bovine γ-globulin; EU, enzyme units; n, native; PAH, p-aminobiphenylate; SSA, sulfosalicylic acid.
Rats were anesthetized with ether and exsanguinatated by aortic puncture 18–20 h after the last i.p. injection.

Chymopapain and nagarse were inactivated by dissolving each enzyme in 6 M guanidine HCl, 10 mM Tris HCl, pH 7.0, to a final concentration of 10 mg/ml (24, 25). After nitrogen was bubbled through the solutions, diluted with distilled water (International Biotechnologies Inc., New Haven, CT) was added to a final concentration of 30 mM. The mixture was then incubated at 37°C for 3 h and iodoacetamide was added to a final concentration of 33 mg/ml, an equal mass of solid Tris base was added simultaneously to prevent rapid pH change (25). The pH of the mixture was adjusted to 8.0 with 1 M Tris base. After 30 min. at 4°C, the solution was exhaustively dialyzed against PBS. Active (0–500 µg/ml) and inactive (0–1,500 µg/ml) chymopapain at varying concentrations were incubated at 25°C for 30 min. with N-acetyl-DL-arginine p-nitroanilide (Sigma Chemical Co.) and active (0–500 µg/ml) and inactive (0–1,500 µg/ml) nagarse at varying concentrations were incubated with N-acetyl-DL-alanine p-nitroanilide (Sigma Chemical Co.) at 25°C for 60 min. The chromogenic peptide substrates were first dissolved at 43.5 mg/ml in dimethyl sulfoxide (Sigma Chemical Co.) and then the change in optical density at 405 nm/min divided by the micromolar extinction coefficient of p-nitroaniline (5.495 x 10⁻³) was taken as the enzymatic activity. Active chymopapain had a specific activity of 0.957 U/mg, whereas inactivated chymopapain had 0.096 U/mg (90% inhibition). Active nagarse had a specific activity of 1.67 U/mg, whereas inactivated nagarse had < 0.034 U/mg (98% inhibition).

Urinalysis. Proteinuria values recorded in all tables were measured by sulfosalicylic acid (SSA)-induced turbidity (26); turbidities of urine samples collected from rats placed in metabolic cages overnight were interpolated into a standard curve with known concentrations of bovine serum albumin (Sigma Chemical Co.) in PBS. The protein concentration in the urine samples was multiplied by the sample volume and by 24 divided by the duration of the collection period in hours (never less than 16) to express the mass of protein excreted per day. Urine collection from each rat was started 24 h after the last i.v. antigen challenge in rats given cBBG, and 6 h after injection in rats given puromycin (pretreatment proteinuria) and 2 h after the last i.p. enzyme dose (post-treatment proteinuria) in all rats. Urinary protein electrophoresis was performed in agarose and SDS-PAGE. For the latter, urine was dialyzed against 4 changes of a 20-fold volume of PBS (27, 28). ELISA for urinary albumin excretion. Microwell plates (Immunoplate Maxisorp, Nunc, Kamstrup, Denmark) were coated for 16 h at 37°C with goat IgG (U. S. Biochemicals) in PBS, containing 2.5 µg/ml of antibody specific for rat albumin. Subsequently, a solution of 10 mg/ml bovine serum albumin (U. S. Biochemicals) in PBS was used to wash the plate twice, and this solution was also incubated in the wells for 1 h at 37°C to block nonspecific sites. After three additional washes, 100 µl of standards (0–3,000 µg/ml) of rat serum albumin in PBS (Cappel Laboratories, Cochranville, PA) or unknown rat urine samples (diluted 1:30 in PBS) were added to duplicate wells. After a 1-h incubation at 25°C, 100 µl of a 200 µg/ml solution of labeled rat albumin (biotinylated in exactly the same manner as the peroxidase and protease enzymes, above) was added to each well. In some cases, varying amounts of 10% trichloracetic acid-soluble fractions of digests of rat albumin, treated in vitro for 3 h at 37°C with 2 U of nagarse and 1 U of chymopapain (60% of the ODmax was soluble in 10% trichloracetic acid), were added to wells coated with anti-rat albumin instead of standard or sample. After another 1-h incubation at 25°C and three washes with PBS, binding of labeled rat albumin was detected by incubation with alkaline-phosphatase-conjugated Extravidin (Sigma Chemical Co., diluted 1:1,000 in PBS), a modified avidin A product with low nonspecific binding characteristics. Finally, after 30 min of incubation at 25°C and three washes with PBS, 4 mg/ml p-nitrophenyl phosphate in 50 mM glycine, 1 mM MgCl2, pH 10.5 was added. Product generation was followed by absorbance at 410 nm in a microplate photometer (Dynatech Laboratories).

Glomerular hemodynamics. Clearance of [3H]inulin and [14C]p-amino-hippurate (PAH, New England Nuclear, Boston, MA) was mea-


Chromatographic separation of proteins was performed by SDS-PAGE and stained with Coomassie Blue. The bands were visualized by UV transillumination and quantified using densitometry with ImageJ software. Relative protein expression was normalized to the housekeeping protein GAPDH. Treatment-induced changes in protein expression were analyzed using two-way ANOVA with Bonferroni post-hoc tests.

Results

Pilot studies: All glomerular suspensions from all rats, optical density was a linear function of time, up to 10 min of observation (all \( r^2 \) ranged from 0.976 to 0.988; all \( P < 0.001 \)). For each rat observed, the optical density developed at 10 min (maximal value in linear phase of reaction) was a linear function of the number of glomeruli added to a standard substrate solution, for each of 12 dilutions in duplicate (\( r^2 \) ranged from 0.838 to 0.946; all \( P < 0.01 \)). The slope of this regression from each individual animal was taken as the enzyme activity (\( \mu \text{EU} \) per glomerulus), and the mean slope of each of the six animals in each group recorded (Table I). The intercepts of the individual regression curves were uniformly < 0.02, whereas the maximums were in the 0.5–0.6 range. All six rats given avidin and b-peroxidase had dense dianinobenzidine aggregates along glomerular capillary walls by light microscopy, whereas none of the rats given avidin plus n-peroxidase, saline plus b-peroxidase or avidin plus saline had glomerular staining above the background observed in normal rat glomeruli. Furthermore, glomeruli isolated from rats given avidin plus b-peroxidase contained 65% more peroxidase activity than glomeruli from rats given saline and b-peroxidase and 73% more activity than glomeruli from rats given avidin and n-peroxidase (both \( P's < 0.01 \), Table I). These results demonstrate that avidin, a naturally cationic protein, can target functional enzyme to the glomerular capillary wall if the enzyme is biotinylated.

Effect of proteases on cBGG-induced nephrosis with moderate proteinuria. All groups of rats had similar initial proteinuria (overall mean 85±12 mg/24 h, \( F \) among the groups = 1.2) after the last antigen challenge. After therapy, rats given saline for 5 d had the greatest proteinuria, 51±10 mg/24 h (Table II). All groups given proteolytic enzymes had significantly less protein excretion than the saline-treated rats, but among these three groups, rats given avidin and b-proteases had significantly less proteinuria than rats given avidin and n-proteases or rats given

| Table I. Targeting of Functional Horseradish Peroxidase to the Glomerulus |
|---------------------------|-------------|------------------|
| Injection                  | No. of rats | Glomerular peroxidase activity | Median (range) of squared correlation coefficients* |
|                           |             |                              | \( \mu \text{EU/glomerulus} \pm SD \)                 |
| Avidin + n-peroxidase      | 6           | 10.8±2.94                   | 0.89 (0.85-0.93)                                      |
| Avidin + b-peroxidase      | 6           | 18.7±2.24                   | 0.92 (0.89-0.95)                                      |
| Saline + b-peroxidase      | 6           | 11.3±2.31                   | 0.87 (0.84-0.90)                                      |
| Avidin + saline            | 6           | 8.6±1.8                     | 0.91 (0.89-0.94)                                      |
| None                      | 6           | 9.2±2.5                     | 0.87 (0.85-0.89)                                      |

* Squares of the correlation coefficients of the regression between enzyme activity (OD/min) and number of glomeruli at 12 different dilutions of the glomerular suspension, in duplicate. 1 Significantly different from normal rats (\( P < 0.05 \)). 2 Significantly different from both other (non-targeted) groups given peroxidase (\( P < 0.01 \)).

Targeted Enzyme Therapy of Experimental Glomerulonephritis 1821
Table II. Effects of Targeted Protease in Active Serum Sickness Glomerulonephritis with Moderate Proteinuria

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of rats</th>
<th>Proteinuria mg/day±SD</th>
<th>Glomerular immune deposits*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>BGG</td>
<td>rat IgG</td>
</tr>
<tr>
<td>Saline</td>
<td>7</td>
<td>71.3±10.4</td>
<td>7 (2.8+)</td>
</tr>
<tr>
<td>Avidin</td>
<td>+ b-protease</td>
<td>17.2±13.2f</td>
<td>5 (1.1+)</td>
</tr>
<tr>
<td></td>
<td>+ n-protease</td>
<td>38.8±8.5l</td>
<td>7 (2.7+)</td>
</tr>
<tr>
<td>B-protease</td>
<td>only</td>
<td>37.8±13.1t</td>
<td>4 (3.0+)</td>
</tr>
</tbody>
</table>

* Data are the number of rats positive (and mean semiquantitative immunofluorescence intensity score of all rats in each group). f P < 0.01 vs. other protease groups, and P < 0.001 vs. saline group by Fisher’s protected t test in ANOVA. l x² = 5.6, P < 0.01 vs. saline group for number of rats positive (relative intensity of immunofluorescence was not considered in the analysis). t P < 0.05 vs. saline group by Fisher’s protected t test in ANOVA.

b-proteases without avidin. Moreover, the rats given avidin and b-proteases revealed glomerular rat IgG and C3 by immunofluorescence less frequently than saline-treated rats (Table II, Fig. 1); the other two groups given untargeted protease had no decrease in the frequency of glomerular immune deposits compared to the saline-treated controls, although the intensities for rat IgG and C3 were appreciably less in these groups than in saline-treated rats. Moreover, we were able to demonstrate, using fluorescein-conjugated antibodies, that avidin is present in the glomeruli of rats given targeted proteases in a distribution identical to that seen with rhodamine conjugated anti-rat IgG, thereby demonstrating localization of avidin to the site of glomerular deposits. Serum antibody titers against cBGG and total serum protein concentrations were indistinguishable among all the groups. Enzyme activity could not be detected in urine collected during the 20 h after the last enzyme dose.

Effect of proteases on cBGG-induced nephrosis with heavy proteinuria. Despite statistically indistinguishable initial levels of protein excretion prior to the onset of therapy, rats treated with avidin and b-proteases had 60% less proteinuria after 5 d of therapy than did rats given saline or avidin alone (P < 0.001, Table III). Rats given untargeted proteases, whether avidin and n-proteases, biotin-saturated avidin plus b-proteases, or b-proteases alone, had more modest reductions in urinary protein that were significantly greater than the level observed in nephrotic rats given targeted protease (P < 0.01). Protease activity in dialyzed urine from treated rats was indistinguishable from that in normal rats (data not shown). Urine protein electrophoreses, in both polyacrylamide and agarose, showed that most of the proteinuria (~85%) was due to intact albumin, without evidence of degradation to smaller polypeptides (data not shown). Finally, recovery of known amounts of protease activity added to saline or to dialyzed nephrotic or normal rat urine was 98-104% (F = 0.78), indicating that no protease inhibitors are present in urine.

There were no differences in the very intense immune deposits of BGG, rat IgG or C3 observed by immunofluorescence among these groups given high doses of cBGG (data not shown). However, rats treated with avidin and b-protease had distinctly fewer and smaller electron dense deposits, which occupied less aggregate space than in rats given biotin-saturated avidin and b-protease (Table III, Fig. 2). Deposits present in targetted or untargeted native protease-treated rats were also smaller in size than those in the group treated with saline, but the difference did not attain significance. The mean aggregate size of deposits per unit basement membrane length in rats given biotin-saturated avidin and biotinyl enzymes was not different from that in rats given saline. Overall, there was a significant correlation between urinary protein excretion and

Figure 1. Targeted protease reduces glomerular deposits in experimental glomerulonephritis. Immunofluorescence micrographs show rat IgG staining in glomeruli from rats rendered nephrotic by immunization with cationic bovine gamma globulin and then treated for 5 d with (A) saline, (B) avidin and biotinyl protease, or (C) avidin and native protease. The biotinyl protease targeted by avidin to the glomerular capillary wall, the site of the immune deposits, significantly reduced immune deposits (B) compared with nephrotic rats given saline (A). The frequency distribution of IgG in nephrotic rats given untargeted protease (C) was similar to saline-treated rats (A), but the intensity was less, more comparable to that in rats treated with targeted protease (B). Biotinyl protease given without avidin (not shown) had an intermediate effect similar to that of native protease given with avidin (C). X350.
Table III. Effects of Targeted Protease in Active Serum Sickness Glomerulonephritis with Severe Proteinuria*

<table>
<thead>
<tr>
<th>Treatment</th>
<th>No. of rats</th>
<th>Proteinuria</th>
<th>Electron microscopic depositsa</th>
<th>Serum cholesterol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Initial</td>
<td>Final</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>mg/d</td>
<td>mm</td>
<td>mg/d</td>
</tr>
<tr>
<td>Saline</td>
<td>16</td>
<td>20±16</td>
<td>89±11.4</td>
<td>35.2±26.7</td>
</tr>
<tr>
<td>Avidin + b-protease</td>
<td>17</td>
<td>218±21</td>
<td>36±7.1**</td>
<td>19.4±9.3*</td>
</tr>
<tr>
<td>Avidin + n-protease</td>
<td>16</td>
<td>208±17</td>
<td>56±6.0**</td>
<td>23.6±7.4</td>
</tr>
<tr>
<td>Avidin, free biotin, and b-protease</td>
<td>10</td>
<td>179±17</td>
<td>65±11.5</td>
<td>47±17.6**</td>
</tr>
<tr>
<td>B-protease only</td>
<td>10</td>
<td>210±12</td>
<td>69±11.8</td>
<td>109±7.4**</td>
</tr>
<tr>
<td>Avidin only</td>
<td>10</td>
<td>188±10</td>
<td>94±14.3</td>
<td>127±10.5</td>
</tr>
</tbody>
</table>

* Data are means±SD. 
† Data are the total area occupied by immune deposits (nm²) per unit length of glomerular basement membrane (nm). Randomly selected rats were studied ultrastructurally. 
‡ Different from saline/no avidin (top row) and avidin only (bottom row) (P ≤ 0.001) by Fisher’s protected t test in ANOVA (F = 4.75, P ≤ 0.001). 
§ Different from all non-targeted enzyme-treated groups (P < 0.01) by Fisher’s protected t test in ANOVA (F = 4.75, P ≤ 0.001). These rats (n = 8) are equivocally different from saline/no avidin (n = 8, t = 1.7, P < 0.1) and different significantly from biotin, saturated avidin + b-protease (n = 6, t = 2.8, P < 0.01) by Fisher’s protected t test in ANOVA (F = 2.9, P < 0.06). 
¶ Different from saline/no avidin and avidin only (P < 0.05) by Fisher’s protected t test in ANOVA (F = 4.75, P ≤ 0.001).

Toxicity studies. Nephrotic rats treated with saline, untargeted protease, or targeted protease had serum concentrations of glutamate—oxaloacetate transaminase, lactic dehydrogenase, or creatine phosphokinase no different from normal rats. Hence, no serum enzymes associated with cytolsis or toxicity were increased in rats treated with proteases. Moreover, at sacrifice, there were no signs of peritonitis, intestinal adhesions, necrosis, or hemorrhage in enzyme treated rats.

Finally, we investigated whether targeted protease therapy affects glomerular hemodynamics (Table V). As previously described (17), neither renal plasma flow nor glomerular filtration rate in nephrotic rats differed from normal age-matched controls. The glomerular filtration rate in protease-treated nephrotic rats did not significantly differ from that in salinetreated nephrotic rats or normal controls. Renal plasma flow in enzyme-treated nephrotic rats was also the same as in salinetreated nephrotic rats and normal controls.

Necessity of enzymatic activity for efficacy of protease therapy. In a separate experiment, we used inactive nagarse and chymopapain for comparison with active enzymes. Among rats with nephrosis induced by cBGG, those treated with active proteases had significantly less proteinuria at the end of treatment than those treated with inactive proteases (Table VI). Urinary albumin excretion was also different (P < 0.001) in rats treated with active enzymes (46.6±7.7 mg/dl) vs. those given inactive proteases (85.8±4.2 mg/dl). Protein excretion in rats treated with active and inactive enzymes was similar, respectively, to that in nephrotic rats treated with active enzymes and saline in previous experiments. Moreover, the 5-d protein excretion (the integral under the curve of proteinuria as a function of time) also was significantly lower in rats treated with active protease (892±102 mg) than in rats given inactive protease (1,072±36.7 mg, P ≤ 0.01). Active, but not inactive, enzymes also reduced serum cholesterol and creatinine levels associated with nephrosis. In this short-term experiment, although modest hypoalbuminemia did develop in nephrotic rats, no differences in serum albumin concentration were observed between rats given active or inactive proteases.

Effect of enzymes on protein excretion in rats with puromycin amino-nucleoside nephrosis. As summarized in Table VII, targeted proteolytic enzymes, given by a regimen identical to that used for rats with cBGG-induced nephrosis, did not influence protein excretion or serum cholesterol concentration in rats with nephrosis induced by puromycin amino nucleoside.

Urinary albumin excretion. In order to exclude any spurious effect on proteinuria determination by SSA, we assayed urinary albumin excretion by ELISA in parallel with SSA. More than 60 rats were studied. Increasing amounts of unlabelled rat albumin, when preincubated in anti-rat albumin-coated microwells, monotonically displaced binding of a fixed amount of biotin-labeled albumin. In fact, in three separate ELISA experiments the optical density was linear with the log of the concentration of unlabelled albumin added over the range of 0–3,000 μg/ml (all r² ≥ 0.97, all P < 0.001). In addition, when standard curves were prepared with serial dilutions of trichloroacetic acid-soluble peptides derived from rat albumin digested in vitro with nagarse/chymopapain, equal in absorbance to serial dilutions of intact unlabelled rat albumin, similar curves relating optical density to concentration were

Targeted Enzyme Therapy of Experimental Glomerulonephritis 1823
Electron-dense deposits in experimental nephrosis induced by cBGG are diminished by targeted protease. (A) Nephrotic rats treated with saline for 5 d had numerous large, coalescent epimembranous deposits of uniform electron density (arrows). (B) Nephrotic rats treated with avidin and biotinyl protease had fewer deposits, which tended to be small. (C) Nephrotic rats treated with avidin and native protease had intermediate numbers of variably sized, electron-dense deposits. ×31,350.

obtained, and linear-least squares regression analysis of the apparent albumin concentrations with the peptides revealed that 88% of the displacement obtained with the whole molecule was obtained with the comparable mass of peptides (i.e., the slope was 0.88, with an $r^2$ of 0.93).

Urine samples from all rats reported in Tables VI and VII and randomly selected rats from Table III were assayed by ELISA for rat albumin content on two separate occasions. There were significant differences in albuminuria among rats with active serum sickness treated with active targeted proteases compared to those treated with inactive enzymes or saline, respectively ($P < 0.01$). However, no differences were observed among rats with puromycin nephrosis, whether treated or not. The results compared well with the values obtained by

White et al.
SSA-induced turbidity by linear-least squares regression. The correlation coefficient comparing the two ELISA runs was similar and not statistically different ($F = 0.02$) from the correlation coefficients comparing each ELISA run with the SSA data (all $r^2 \geq 0.83$, all $P < 0.001$). Although both ELISA vs. SSA produced slopes significantly ($P < 0.01$) < 1 (0.86 and 0.72), the slope between the two ELISA determinations for each of the 40 specimens was nearly unity (1.05, $P = NS$ vs. 1.00). Most likely, this is due to a selectivity index of ~80%, since the ELISA only detects albumin, whereas the SSA assay detects albumin and other proteins as well. Among randomly selected urines, when the total protein (by SSA) was multiplied by the fraction of the area under the densitometric tracing of urine protein electrophoresis occupied by albumin and plotted against the ELISA values for albuminuria, even better correlations (all $r^2 \geq 0.92$, all $P < 0.001$) were obtained. Hence, enzyme therapy does not have a nonspecific effect on proteinuria as quantified by SSA. Moreover, treatment with active protease does not result in digestion of urine protein to a significant degree. Since the selectivity index in cBGG-induced nephrosis is variable, we consider total protein, best measured by SSA, the preferable method of assay; hence, all table entries are proteinuria determined by SSA.

### Discussion

The data presented here extend earlier observations on the efficacy of protease therapy of experimental glomerulonephritis (14–16). In the current work we show that systemic administration of non-toxic doses of proteases, especially when targeted to the glomerular capillary wall, can remove glomerular immune deposits in a different model of immune complex glomerulonephritis, namely, active serum sickness induced by immunization and challenge of rats with cBGG. Decreased glomerular deposits were observed in some cases by both semiquantitative immunofluorescence and quantitative electron microscopy. Moreover, protease therapy improved several parameters of glomerular function in cBGG-induced nephrosis, including proteinuria and lipidemia.

In theory, several mechanisms could contribute to our observations. Urinary excretion of proteases along with albumin and other serum proteins could promote digestion of excreted protein already within the urine to the point of undetectability by turbidimetry. In this scenario, decreased proteinuria would be an analytical artefact rather than an indicator of improved glomerular permselectivity. This possibility can be excluded on several grounds. First, in the present study we could not detect increased proteolytic activity in the urine of rats given proteases, nor in our earlier studies (14) did a 4-h urine collection started immediately after protease injection contain detectable enzyme activity. Lack of enzymatic activity cannot be ascribed to the presence of protease inhibitors in the urine since the recovery of enzymatic activity when exogenous protease was deliberately added to normal or nephrotic rat urine uniformly exceeded 88%. Secondly, peptides generated by incubation of rat serum in vitro with the enzymes used (14) were not observed in electrophoresis of urine from enzyme-treated rats, and the staining intensity of the albumin bands in such electrophoreses were consistent with the measured protein concentration. Moreover, such peptides are readily detected in the ELISA for urinary albumin, but were not detected in urine for non-toxic doses of proteases.
samples from rats given protease. Thirdly, although rats given b-proteases alone or avidin with n-proteases had higher serum levels of enzyme (potentially increasing filtered protease as well), these therapies were less effective at reducing proteinuria than was targeted enzyme (avidin plus b-proteases). Fourthly, this mechanism cannot explain the enzyme-induced reductions in glomerular immune deposits or the attenuation of hyperlipidemia and creatininemia. Fifthly, use of nonproteolytic enzymes capable of removing glomerular immune deposits induced with a polysaccharide antigen ameliorates proteinuria, despite absence of any proteolytic activity in the urine (29). Finally, the failure of proteases to ameliorate proteinuria and hyperlipidemia in puromycin nephrosis is inconsistent with an effect of protease on protein in the urine (as well as with a nonspecific effect of protease on glomerular permeability).

Another theoretical possibility to account for both diminished glomerular immune deposits and decreased proteinuria would be diminished glomerular delivery of immune reactants or decreased filtered load of serum proteins, either from reduced glomerular perfusion, sequestration, or catabolism. However, hemodynamic studies clearly showed no reduction in glomerular perfusion due to enzyme therapy. Moreover, we observed no change in the concentration, size distribution, or electrophoretic mobility of serum proteins in rats treated with proteases, and the serum antibody response to cBGG was identical in treated versus untreated nephrotic rats. Since the model of nephrosis used is complement independent (19), protease effects on the complement system could not have influenced proteinuria.

Proteases might enhance sequestration, catabolism, and/or clearance of circulating immune complexes preferentially compared to other serum proteins, thus resulting in diminished delivery to the glomerulus. Such an explanation is inconsistent with the observation that targeted enzymes were more effective than untargeted enzymes (b-proteases alone or avidin plus n-proteases) since lower serum enzyme levels were observed with targeted than with untargeted proteases.

The explanation for the therapeutic effect that we favor is the most direct, namely, that the administered enzymes degrade immune complexes in situ within glomeruli. Neither proteinuria nor glomerular immune deposits increase further after onset of nephrosis in the cBGG-induced model (17). Since, as already discussed, decrements in glomerular delivery of immune deposits are not plausible, we favor the concept that proteases accelerate removal of immune reactants already deposited in glomeruli. It is conceivable, as well, that enzyme treatment acts preferentially at the surface of glomerular immune deposits in such a way as to prevent expansion of the immune lattice, i.e., some of the efficacy of enzyme therapy may derive from inhibition of the growth of deposits rather than their dissolution. Enzyme action in situ in the glomerulus is the only interpretation which readily explains all the observations in this and previous publications (14–16, 29).

Enzymes deliberately targeted to the anionic glomerular capillary wall, where the cationic immune complexes bound, were more effective than untargeted enzymes at reducing glomerular deposits, decreasing proteinuria, and ameliorating hyperlipidemia and creatininemia. We therefore conclude that the interaction of avidin with biotinylated proteases is important, and propose that this interaction improves efficacy because the naturally cationic avidin targets the b-proteases to the same sites where cationic immune complexes have lodged, thereby promoting enzyme-substrate interaction. Targeting would also accelerate removal of b-proteases from the circulation by promoting their binding to avidin-containing sites such as the glomerular basement membrane. Such an effect can explain the lower enzyme activity observed in the sera of rats given targeted proteases compared to sera of rats given equal activity doses of nontargeted proteases.

In conclusion, we have demonstrated that proteases, especially when targeted, given systemically at nontoxic doses to nephrotic rats can ameliorate proteinuria, creatininemia, and hyperlipidemia, the cardinal features of the nephrotic syndrome. Targeted proteases can also reduce glomerular immune deposits. With further work and refinement it is conceivable that protease therapy could prove practical for patient therapy. In addition to its therapeutic potential, administration of appropriate enzymes to animals with experimental glomerulonephritis can be a useful tool for study of glomerular pathophysiology.

### Table VI. Effects of Active vs. Inactive Targeted Protease in Active Serum Sickness Glomerulonephritis with Severe Proteinuria

<table>
<thead>
<tr>
<th>Glomerulonephritis induction</th>
<th>Enzyme treatment</th>
<th>Number of rats</th>
<th>Serum concentration</th>
<th>Proteinuria</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>mg/dl</td>
<td>mg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cBGG active</td>
<td>8</td>
<td>101±8.5</td>
<td>2.63±0.16†</td>
<td>300±18†</td>
</tr>
<tr>
<td></td>
<td>cBGG inactive</td>
<td>8</td>
<td>145±13*</td>
<td>2.68±0.14†</td>
<td>299±19†</td>
</tr>
<tr>
<td></td>
<td>none</td>
<td>6</td>
<td>69±7.7</td>
<td>3.42±0.05</td>
<td>9.3±3.9</td>
</tr>
</tbody>
</table>

* Significant difference (P < 0.001) vs. control and cBGG glomerulonephritis treated with active enzymes (F = 11.8 for cholesterol, 15.6 for creatinine, 10.8 for final proteinuria). † Significant difference (P < 0.001) vs. control (F = 10.8).

### Table VII. Lack of Effect of Targeted Protease Therapy in Puromycin Aminonucleoside Nephrosis*

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of rats</th>
<th>Serum cholesterol</th>
<th>Proteinuria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>mg/dl</td>
<td>mg/d</td>
</tr>
<tr>
<td>Enzymes</td>
<td>8</td>
<td>272±14</td>
<td>304±15</td>
</tr>
<tr>
<td>Saline</td>
<td>8</td>
<td>300±10</td>
<td>328±27</td>
</tr>
</tbody>
</table>

* There were no statistically significant differences between the groups for any value.
Acknowledgments

The authors are grateful to Michael J. Dunn and John R. Sedor for advice, to Ramzi Cotran and Helmut Renne for suggesting the puromycin aminonucleoside experiment, to Nancy J. Urankar and Claudia Kesselheim for excellent technical help, and to Sara A. Cechner for typing.

This work was supported by National Institutes of Health grants DK-38544, AI-26449, and HL-37117.

References